Skip to main content

Table 2 Renal function and biochemical data of patients with β-Thalassemia Major and their subgroups based on chelation treatment in the current and previous study

From: Renal function in β-thalassemia major patients treated with two different iron-chelation regimes

Parameter
(normal range)
Current study Previous study
Chelator DFX
n = 26
DFO +/−DFP
n = 10
Total
n = 36
DFO
n = 29
Gender (M:F) (13:13) (5:5) (18:18) (13:16)
Age 19.4 ± 9.3 24.8 ± 10.2 20.9 ± 9.5 14 ± 8.1
Serum Cr (mg/dl)
(0.6–1.1)
0.64 ± 0.11 0.6 ± 0.14 0.63 ± 0.12 0.54 ± 0.09
Serum sodium (meq/l)
(135–145)
137.6 ± 1.7 137.1 ± 2.2 137 ± 1.8 139 ± 2
Serum potassium (meq/l)
(3.5–5.5)
4.12 ± 0.3 4.17 ± 0.19 4.12 ± 0.2 4.25 ± 4.6
Serum uric acid (mg/dl)
(2.5–7.5)
4.3 ± 1.2 4.3 ± 1.2 4.54 ± 1.2 4.3 ± 0.9
GFR (ml/min per 1.73 m2)
(> 60)
100.9 ± 17 114 ± 22 104.6 ± 19 109.7 ± 23.2
eGFR
(ml/min per 1.73 m2)
113.2 ± 21 124.8 ± 26 116.4 ± 23 113.5 ± 26
uNAG (IU/l)
(< 12)
10.42 ± 6.1* 5.33 ± 2.7* 9.07 ± 5.8 10.76 ± 6.7
Abnormal uNAG (8/26) 30.7% (1/10) 10% (9/36) 25% (8/29) 27.5%
Patients with ProtU> 150 mg/d or equivalent prot/ Cr ratio (2/26) 7.7% (2/10) 20% (4/36) 11.1%  
Urine Ca/Cr
(< 0.14)
0.229 ± 0.2 0.173 ± 0.1 0.21 ± 0.2 0.09 ± 0.1**
Abnormal Urine Ca/Cr (8/26) 30.7% (2/10) 20% (10/36) 27.8% (2/29) 6.9%
FeNa (%) 0.84 ± 0.245 0.70 ± 0.33 0.8 ± 0.43 0.94 ± 0.61
FeK (%)
(4–16)
13.2 ± 8.3 13.6 ± 8.9 13.3 ± 8.3 16 ± 8.3
UAE (mg/dl GFR)
(< 0.56)
0.7 ± 0.24 0.56 ± 0.19 0.66 ± 0.23 0.75 ± 0.24
Abnormal UAE (18/26) 69.2% (5/10) 50% (23/36) 63.8% (21/29) 72.%
TmP/GFR (mg/dl)
(3–5)
4.63 ± 0.68 4.75 ± 0.95 4.67 ± 0.75 4.89 ± 1.15
Urine osmolality (mosmol/kg)
(50–1200)
678.2 ± 188 705 ± 222 685.7 ± 193 757 ± 170
  1. Data expressed as mean ± SD
  2. *P < 0.05 between chelation-based subgroups of β-thalassemia patients
  3. **P < 0.05 between total patients in the current study and those in the previous study